Evidence map›Paper›PMID 37662600›Full record

ArticleCase reports in rheumatology2023

A Case of an Elderly Woman Who Developed Corneal Perforation in the Clinical Course of Myeloperoxidase Positive Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Shuhei Kobayashi, Makoto Harada, Aiko Yamada, Yasuhiro Iesato, Koji Hashimoto, Yuji Kamijo

Open access · goldAbstract readCase Reports
In one paragraph

Article in Case reports in rheumatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Shuhei KobayashiDepartment of Nephrology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
Makoto HaradaDepartment of Nephrology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.ORCID https://orcid.org/0000-0002-6209-7683
Aiko YamadaDepartment of Nephrology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.
Yasuhiro IesatoDepartment of Ophthalmology, Shinshu University School of Medicine, 3-1-1, Asahi, Matsumoto 390-8621, Japan.ORCID https://orcid.org/0000-0003-1578-0401
Koji HashimotoDepartment of Nephrology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.ORCID https://orcid.org/0000-0002-8854-2810
Yuji KamijoDepartment of Nephrology, Shinshu University School of Medicine, Matsumoto 390-8621, Japan.ORCID https://orcid.org/0000-0001-8077-891X
Shinshu University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antineutrophil cytoplasmic antibody- (ANCA-) associated vasculitis (AAV) is a systemic vasculitis characterized by ANCA positivity and categorized into three main types: microscopic polyangiitis, granulomatosis with polyangiitis, and eosinophilic granulomatous with polyangiitis. Although AAV leads to systemic organ injury, such as of the lungs, kidneys, nerves, and skin, patients with AAV sometimes develop ocular lesions. Here, we report the case of an elderly woman who had been treated for AAV for seven years. She developed scleritis and relapsed twice, with elevation of serum disease markers such as ANCA titer and C-reactive protein. After the decline of these markers due to treatment with additional medication, her scleritis relapsed again and caused a corneal ulcer, which resulted in perforation without obvious marker elevation. She did not present with any symptoms of organ injury, except for ocular lesions. She was treated with surgery, followed by methylprednisolone and rituximab therapy. Subsequently, her ocular lesions and symptoms improved, and she did not relapse. AAV can cause various ocular manifestations. Although C-reactive protein and ANCA titers are useful markers of disease activity and the relapse of AAV complications, including ocular lesions, these markers do not always increase at the time of worsening ocular lesions. Therefore, it is important for clinicians treating patients with AAV to pay careful attention to serum data and physical findings, including the eyes.

Identifiers

PMID37662600
PMCPMC10474959
OpenAlexW4386189363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.